Rezolute Inc Cash Flow Conversion Efficiency
Rezolute Inc cash flow conversion efficiency. Based on the latest financial reports, Rezolute Inc (RZLT) has a cash flow conversion efficiency ratio of -0.118x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.73 Million) by net assets ($116.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rezolute Inc (2012–2025)
Cash flow conversion efficiency of Rezolute Inc from 2012 to 2025. This chart illustrates how Rezolute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RZLT stock price and chart for real-time trading data and today's change.
Rezolute Inc Cash Flow Conversion Ratio Explained
Rezolute Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rezolute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rezolute Inc ranked by their cash flow conversion efficiency. Also see RZLT market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Verano Holdings Corp
NEO:VRNO
|
0.045x |
|
Hibiscus Petroleum BHD
KLSE:5199
|
-0.186x |
|
Sports Gear Co. Ltd
TW:6768
|
-0.047x |
|
ElringKlinger AG
F:ZIL2
|
0.233x |
|
Lumina Gold Corp
V:LUM
|
0.070x |
|
PowerFleet, Inc.
NASDAQ:AIOT
|
0.017x |
|
Trilogy Metals Inc
TO:TMQ
|
-0.009x |
|
NVE Corporation
NASDAQ:NVEC
|
0.089x |
Annual Cash Flow Conversion Efficiency for Rezolute Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rezolute Inc from 2012 to 2025. Review Rezolute Inc (RZLT) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $162.13 Million | $-69.08 Million | -0.426x | +10.13% |
| 2024-06-30 | $121.00 Million | $-57.37 Million | -0.474x | -23.82% |
| 2023-06-30 | $116.17 Million | $-44.48 Million | -0.383x | -44.46% |
| 2022-06-30 | $149.47 Million | $-39.62 Million | -0.265x | +66.16% |
| 2021-06-30 | $26.10 Million | $-20.44 Million | -0.783x | +76.13% |
| 2020-06-30 | $7.37 Million | $-24.17 Million | -3.281x | +62.43% |
| 2019-06-30 | $1.75 Million | $-15.30 Million | -8.735x | -345.15% |
| 2018-06-30 | $-3.96 Million | $-14.11 Million | 3.563x | +328.28% |
| 2017-06-30 | $8.53 Million | $-13.31 Million | -1.561x | -30.56% |
| 2016-06-30 | $8.77 Million | $-10.49 Million | -1.196x | -52.91% |
| 2015-06-30 | $9.05 Million | $-7.08 Million | -0.782x | -58.15% |
| 2014-06-30 | $6.41 Million | $-3.17 Million | -0.494x | -226.40% |
| 2013-06-30 | $-4.16 Million | $-1.63 Million | 0.391x | +1147.91% |
| 2012-06-30 | $-1.29 Million | $-40.40K | 0.031x | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more